Finanzen von Anebulo Pharmaceuticals Inc (ANEB)ANEBAnebulo Pharmaceuticals Inc

Evaluating the bottom line, Anebulo Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -69.69%, provide a clear picture of how effectively ANEB converts its operational activities into shareholder value.

In the context of the broader market, ANEB competes directly with industry leaders such as COSM and COCP. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ANEB's gross margin of N/A stands against COSM's 6.12% and COCP's 100.00%. Such benchmarking helps identify whether Anebulo Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

In Q2 2026, revenue remained at 0 with no growth. Net income dropped to -$1,999,397 (-18.82% YoY), and EPS fell to -0.05 (-44.44% YoY). Gross margin remained at 0 with no improvement.